1-7 of 7
nilotinib
Close
Sort by
Journal Articles

A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety

Clinical Trials & Observations
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana Patterson, Jill Samis, Paola Aimone, Alex Allepuz, Ksenia Titorenko, Darintr Sosothikul
Journal: Blood Advances
Blood Adv (2021) 5 (14): 2925–2934.
https://doi.org/10.1182/bloodadvances.2020003759
Published: 2021
Includes: Supplemental data
Journal Articles

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

Clinical Trials & Observations
Claudia Vener, Rita Banzi, Federico Ambrogi, Annalisa Ferrero, Giuseppe Saglio, Gabriella Pravettoni, Milena Sant
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2723–2735.
https://doi.org/10.1182/bloodadvances.2019001329
Published: 2020
Includes: Supplemental data
Journal Articles

Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation

Clinical Trials & Observations
Chihiro Yamamoto, Hirotomo Nakashima, Takashi Ikeda, Shin-ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Takashi Nagayama, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Miyuki Sugimoto, Yuko Ishihara, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Shin-ichiro Fujiwara, Masuzu Ueda, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3266–3277.
https://doi.org/10.1182/bloodadvances.2019000745
Published: 2019
Includes: Supplemental data
Journal Articles

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

Clinical Trials & Observations
Chung H. Kok, David T. Yeung, Liu Lu, Dale B. Watkins, Tamara M. Leclercq, Phuong Dang, Verity A. Saunders, John Reynolds, Deborah L. White, Timothy P. Hughes
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1610–1621.
https://doi.org/10.1182/bloodadvances.2019000195
Published: 2019
Includes: Supplemental data
Journal Articles

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia

Clinical Trials & Observations
Adrian G. Minson, Katherine Cummins, Lucy Fox, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Shaun Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf, Faye Putt, Andrew Grigg
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1084–1091.
https://doi.org/10.1182/bloodadvances.2018028035
Published: 2019
Includes: Supplemental data
Journal Articles

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Clinical Trials & Observations
Preetesh Jain, Hagop Kantarjian, Prajwal C. Boddu, Graciela M. Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Princy Sam, Hycienth Ahaneku, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2019) 3 (6): 851–861.
https://doi.org/10.1182/bloodadvances.2018025874
Published: 2019
Includes: Supplemental data
Journal Articles

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure

Clinical Trials & Observations
Justine E. Marum, David T. Yeung, Leanne Purins, John Reynolds, Wendy T. Parker, Doris Stangl, Paul P. S. Wang, David J. Price, Jonathan Tuke, Andreas W. Schreiber, Hamish S. Scott, Timothy P. Hughes, Susan Branford
Journal: Blood Advances
Blood Adv (2017) 1 (18): 1369–1381.
https://doi.org/10.1182/bloodadvances.2017006825
Published: 2017
Includes: Supplemental data